On June 18, 2025, the "Steady Progress, Long-term Vision: China’s ESG Leaders Report 2025" was officially released at the China Responsible Investment Forum Summer Summit. Thanks to its outstanding performance in environmental management, social responsibility, and governance practices, JiuZhou Pharma was successfully selected.

The report selected 138 A-share listed companies with an ESG rating of A- or higher from the pool of those rated by "Shengdao Ronglv ESG." The selection process was based on the principle of choosing the best from the best, considering companies that ranked in the top 10 within their respective industries and had no significant ESG risk events in the past three years. These selected companies account for 2.6% of the total A-share companies. The average ESG score of the selected companies was 73.99, which is 20.05 points higher than that of non-selected companies. Across the three ESG dimensions, the selected companies showed significant leadership, particularly in the environmental dimension, where their average score was 28.87 points higher than that of non-selected companies.

The release of the "Steady Progress, Long-term Vision: China’s ESG Leaders Report 2025" showcases the progress that Chinese companies have made in ESG practices. The companies listed in the report represent the benchmark for A-share listed companies in terms of sustainable development. The data indicates that Chinese companies are rapidly increasing their focus on ESG, with leading companies already demonstrating a clear guiding effect. In the current challenging environment, solid ESG management is not only an intrinsic requirement for companies to ensure long-term stability and enhance their resilience to risks but also a key pathway to align with national strategies and achieve high-quality development. Moving forward, JiuZhou Pharma will continue to strengthen its ESG governance capabilities, supported by quantifiable performance, transparent disclosures, and collaborative mechanisms, contributing its "JiuZhou Solution" to the sustainable transformation of the pharmaceutical industry.

Shengdao Ronglv is a leading green finance and responsible investment professional service institution in China, offering services such as responsible investment and ESG assessments, green bond evaluations and certifications, and green finance consulting. As the first signatory of the Principles for Responsible Investment (PRI) in China, a founding member of the China Responsible Investment Forum (China SIF), and a governing body member of the Green Finance Professional Committee of the China Finance Society, Shengdao Ronglv’s ESG ratings cover all listed companies in China. It helps investment institutions understand the level of corporate sustainability and the ESG risks they face.